Dear Colleagues,
Welcome to the April 2011 issue of Science Speaks!
This month's issue of Science Speaks focuses on North America, specifically minorities in U.S. clinical trials and Canada's biotech industry.
Take a look also at this month's Biotech News section a view on the recent merger between French pharma and U.S. biotech.
Please visit our website at www.languageconnections.com to learn more about our services and publications.
Enjoy!
|
Minority Representation in U.S. Clinical Trials
|
 Although a number of commonly studied diseases are prevalent among many populations, ethnic and racial minority
groups in the United States
continue to be under-represented in clinical research. In case you missed our article published in the November 2009 issue of GCPj entitled "The Missing Minorities" we offer you this opportunity. |
Canada's Biotech Industry
|
Canada's
position as a leader in biotechnology - currently one of the top five countries
in the world - is a reflection of the country's large investment in the biotech sector
and biomedical research.
With public firms making up 20%, the number
of biotech companies in the country continues to grow accompanied by an increase in revenues. On a global scale, the total number of biotech firms in Canada outnumbers that of the UK and Japan.
Read more...
|
Biotech News:
Will Sanofi speak French to Genzyme?
|
 Sanofi-Aventis, a major French pharmaceutical company, recently announced
that it has entered into a deal to buy Genzyme, the Cambridge, MA-based
biotech company that dominates the rare disease drug market. Sanofi's
offer to buy Genzyme at $74 a share speaks for the French company's need
to obtain new biologic products. |
